Every Man with Prostate Cancer
DESERVES A BETTER ANSWER
Not all biomarker tests are the same. When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. The Prolaris® test from Myriad Genetics is the only biomarker test on the market with both an Active Surveillance Threshold and a Multi-Treatment Modality Threshold.
Endpoints Matter when Selecting a Biomarker
It is critical to understand what information you are getting when selecting a biomarker. The Prolaris test looks at the disease endpoints that matter most and has been rigorously studied and proven to meet ALL of its primary endpoints.
10-year disease-specific mortality when considering conservative management
10-year risk of developing metastasis when considering definitive treatment
Other biomarker tests, like Oncotype DX and Decipher look at endpoints like adverse pathology. A recent independent study by Memorial Sloan Kettering called into question the use of adverse pathology for treatment recommendations for low-risk men. In a head-to-head study comparing Prolaris to adverse pathology, Prolaris was found to be 2.5 times better at predicting disease outcomes.